Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein N3 (FOXN3) is a member of the forkhead/winged-helix family of transcription factors encoded by the FOXN3 gene on human chromosome 14q31.3-q32.11[1][5]. FOXN3 primarily acts as a transcriptional repressor and has critical roles in cell cycle control, particularly in the DNA damage response where it mediates cell cycle arrest and facilitates DNA repair to maintain genomic stability[2][3][5]. FOXN3 can suppress tumor proliferation through blocking cyclin-dependent kinases and modulating the AKT/MDM2/p53 signaling pathway[4][5]. It is frequently downregulated in various cancers, where reduced FOXN3 expression correlates with poorer prognosis[2][4][5]. However, FOXN3 also has context-dependent roles and can act as an oncogene in specific cancers such as pancreatic cancer[2]. It forms complexes with cofactors, such as NEAT1 and SIN3A, affecting gene expression networks involved in cancer cell migration and metastasis[2]. No drugs directly targeting FOXN3 are currently known, and it is not recognized as a routine pharmacological target; however, FOXN3 expression is being investigated as a prognostic biomarker in select malignancies[2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box protein N3 (FOXN3).